- AI
- Molecular Imaging
- CT
- X-Ray
- Ultrasound
- MRI
- Facility Management
- Mammography
Johnson & Johnson to buy Biopsys
Healthcare giant Johnson & Johnson of New Brunswick, NJ, has agreed to buy minimally invasive surgical developer Biopsys Medical of Irvine, CA, in a stock swap valued at $310 million. Biopsys manufactures Mammotome, a biopsy gun that uses a vacuum
Healthcare giant Johnson & Johnson of New Brunswick, NJ, has agreed to buy minimally invasive surgical developer Biopsys Medical of Irvine, CA, in a stock swap valued at $310 million. Biopsys manufactures Mammotome, a biopsy gun that uses a vacuum method for removing breast tissue. The merger is subject to approval by Biopsys shareholders and regulatory authorities.
The amount of Johnson & Johnson stock that will be issued for each Biopsys share will be based on a formula in which $27.55 will be divided by the average closing price per J&J share for each of the 20 trading days preceding the last full trading day prior to a meeting of Biopsys shareholders to approve the merger. Biopsys shares closed at $26.69 the day the merger was announced.
Could a Deep Learning Model for Mammography Improve Prediction of DCIS and Invasive Breast Cancer?
April 15th 2024Artificial intelligence (AI) assessment of mammography images may significantly enhance the prediction of invasive breast cancer and ductal carcinoma in situ (DCIS) in women with breast cancer, according to new research presented at the Society for Breast Imaging (SBI) conference.
MRI-Based AI Model Shows Promise in Predicting Lymph Node Metastasis with Breast Cancer
April 15th 2024For the prediction of axillary lymph node metastasis in patients with breast cancer, an MRI-based, 4D convolutional neural network model demonstrated an AUC of 87 percent and sensitivity of 89 percent, according to new research.
